Neurogenic switching: a hypothesis for a mechanism for shifting the site of inflammation in allergy and chemical sensitivity. by Meggs, W J
M 919, ~~. S - -.
Neurogenic Switching: A Hypothesis for a
Mechanism for Shifting the Site of Inflammation
in Allergy and Chemical Sensitivity
William J. Meggs
Department of Emergency Medicine, East Carolina University School of Medicine,
Greenville, NC 27858 USA and New York City Poison Center, New York, NY 10016 USA
Neurogenic switching s p*ows4d::'kA" hwothcsisforam~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.................aa
hypothesis for a mecaisi' wFI:.
stimulus at one site can..lead.t. .....m.
tion at adistant site. Neo i
tion occurs when substance P ni` o.th..e. r :
neuropeptides released m s .e.
rons produce an inflammatory response,
whereas unogeic inflammat o.n.results
from the binding ofantgen to an r
leukocyte receptors. There is acr.ossoer:
mechanism between ..:es ..; .tw .....
inflammation. Neuon s ispr-
posed to resultwhen a so imuse fm.
asite ofacvation is rerot.. ....t....ce
nervous system to a distant l o pro-
*duce neurgenic inflammation::a d.e s.e. o
location. Neurogenic svc ..g..a psb
explanation for systemic aphyla.`is,: ini
which inoculation ofthe skin .or gt with
antge produXces sytemi syp1m inv
ing. the respiratory and cut. se,
and anexperimentalmodel of . is
consistent with this hypothesis. od-l
gy-iducing asthma, urticaria,ar:thritsd.d
..fibromyhga are other poss ealo
:esrogcswitng. N n w
provides a mechanism to e h
...... ......................................................... -gens -infectious agents, irtns adpsi
bly em.otional stress can ea c,odi-
tons such as migaine, asthma, n artri
tis. Because neurogenic Sinam.atio..o.:s
known to be triggered by emi. po-
surm, it mayplay arole in thesickb
syndrome and dhe multiple chcal sensi-
ivity syndrome. Thus _.rgnc tching
would explain how the p irtory irrita_a..n.
lead to smptoms at othersies i ts
orders. Key words: allergy, l
-arthritis, asthma,ceia estvt,fo
aler, in t, mig
infation, substa P. :P:
103:54-56 (1995)
There are two grand, interrelated systems
by which foreign materials can produce
inflammation in a tissue. Immunogenic
inflammation arises when an antigen binds
to an antibody or leukocyte receptor to
trigger an inflammatory cascade. Prior sen-
sitization is required, and the inflammato-
ry response can take several forms includ-
ing immediate and cell-mediated hyper-
sensitivity. Neurogenic inflammation
occurs when a chemical combines with the
chemical irritant receptors on sensory
nerves, leading to the release of substance
P and other inflammatory neuropeptides
(1). Neurogenic inflammation can also
arise when a nerve impulse travels down an
axon to release substance P at the terminus
(2,3). There is an interplay between
immunogenic and neurogenic inflamma-
tion, in that substance P can degranulate
mast cells and histamine can activate sen-
sory nerves (4), as depicted in Figure 1.
This figure is a simplification, in that a
host of other cells and mediators are
involved in inflammation. However, the
cells and mediators depicted in the figure
dominate the type I immediate hypersensi-
tivity response to allergens and sensitivity
to chemicals. Clinically, the two forms
may lead to the same end result. For exam-
ple, asthma can be initiated by allergens
(immunogenic inflammation) or chemical
irritants (neurogenic inflammation).
One puzzling feature of the inflamma-
tory response is that a stimulus in one tis-
sue can sometimes lead to inflammation at
another site. Food allergy provides an
example. Ingestion of a food allergen can
produce gastrointestinal symptoms, with
diarrhea, abdominal pain, bloating, and
emesis arising from the direct degranula-
tion of gut mast cells with local mediator
release. A small percentage ofpatients with
food allergy develop symptoms at other
sites, manifesting as asthma (5), rhinitis
(6), or urticaria ('). Food hypersensitivity
can also manifest as arthritis (8,9) and
migraine (10,11). Histamine from gut
mast cells could bind to sensory nerves to
produce an afferent signal, which could be
rerouted via the central nervous system to
another site, as depicted in Figure 1. This
neurogenic switching could then explain
the diverse manifestations offood allergy.
Systemic anaphylaxis may be a mani-
festation of neurogenic switching.
Cutaneous inoculation with an antigen,
such as a bee sting, or gut inoculation, as
in the ingestion of a food or drug, can
affect multiple organ systems immediately.
Respiratory involvement with bron-
chospasm, bronchorrhea, and laryngeal
edema, gastrointestinal symptoms, skin
involvement away from the site ofinocula-
tion with diffuse flushing or urticaria, and
cardiovascular symptoms with hypotension
from vasodilation can all arise. A role for
the nervous system in systemic anaphylaxis
has been demonstrated in experimental
models. It is known that vagotomy pro-
tects rats from lethal anaphylaxis without
changing the production of antibody or
histamine release (12). Experimental
lesions of the anterior hypothalamus
lessens the anaphylactic reaction in a
guineapig model (13). Neurogenic switch-
ing may be the mechanism for this
observed modulation ofanaphylaxis by the
nervous system, though other mechanisms
such as a generalized decrease in parasym-
pathetic tone should be considered.
Gustatory rhinitis is another phenome-
non in which neurogenic switching may
play a role. In this syndrome, rhinorrhea,
nasal congestion, and facial sweating devel-
op after the ingestion of spicy foods.
Ingested irritants such as capsaicin, the
active ingredient in chili peppers, interact
with branches of the trigeminal nerve
innervating the oral cavity. The efferent
signal is switched to the nose and face
(14).
Sick building syndrome (15), in which
diverse symptoms such as headache and
difficulty with concentration accompany
mucosal irritation in occupants ofpoorly
ventilated buildings, may involve neuro-
genic switching. The site of inflammation
could be switched from the airway to the
brain, causing vasodilation and edema. An
alternative hypothesis is that lymphocytes
at the site ofstimulation release mediators
which circulate to the brain and cause
symptoms (16). Interleukin-I and inter-
leukin-2 are known to affect cerebral func-
tion in animal models (17,18). This type
ofswitching might be termed "immuno-
genicswitching."
Neurogenic switching may play a role
in multiple chemical sensitivity syndrome
(19-21), which is thought to be mediated
by neurogenic inflammation (22). In this
syndrome, exposure to respiratory irritants
triggers symptoms in more than one organ
system. An individual patient with chemi-
cal sensitivities often has recurrent sites of
symptomatology and inflammation which
reoccur with a well-defined pattern.
Myalgias in the nape of the neck, inflam-
mation ofa particular set ofjoints, or gas-
trointestinal symptoms might occur over
and over again in a single patient. The
establishment of a neuronal pathway so
that stimulation ofirritant receptors in the
airway, for example, leads to inflammation
in a given tissue may be the mechanism for
involvement ofsecondary organ systems.
Neurogenic inflammation is thought
to play a role in rheumatoid arthritis (23),
migraine headache (24,25), and fibromyal-
gia (26). The basis ofthese conditions may
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Figure 1. Interplay between neurogenic and immunogenic inflammation, with neurogenic switching ofthe
inflammation site. (A) Chemical irritants (Ch) bind sensory neurons to release neuropeptides including
substance P (Sp). An afferent signal travels to the central nervous system (CNS). (B) Antigen (Ag) binds
IgE molecules on mast cells to release mast cell mediators including histamine (H). Histamine binds to
receptors on sensory neurons, and substance P binds to receptors on mast cells. (C) Both histamine and
substance P can bind effector cells, such as endothelial cells, mucus-secreting cells, and bronchial
smooth muscle cells to produce inflammation. (D) Neurogenic switching occurs when an efferent signal
from the CNS causes release of neuropeptides at another site, producing inflammation atthe second site
without local stimulation.
be an acquired neuronal pathway that
shunts inflammatory stimuli to the joints,
cerebral vasculature, or muscles, respective-
ly. Then, inflammatory stimuli arising
from allergens, chemical irritants, or infec-
tious agents could lead to a flare in inflam-
mation at the diseased site. Emotional
stress might also lead to neuronal signals
that could result in inflammation at sus-
ceptible sites.
To summarize, it has been pointed out
that the multiple organ system involve-
ment that has been so problematic in
understanding chemical sensitivity also
occurs in allergy. A single mechanism may
underlie this switching of the site of in-
flammation in both allergy and chemical
sensitivity. It is hypothesized that neuro-
genic switching is one possible mechanism
by which stimulation of inflammation at
one site can lead to inflammation at anoth-
er (Fig. 1). An exposure to either an aller-
gen or chemical irritant at one site leads to
a sensory nerve impulse. For allergens,
mast cell degranulation leads to the release
ofhistamine and other mediators, and hist-
amine binds receptors on sensory nerves.
For chemical irritants, receptors on periph-
eral nerves are directly triggered. When the
impulse reaches the central nervous system,
it is redirected to another peripheral loca-
tion, leading to the release of substance P
and other neuropeptides, producing in-
flammation at the second site.
An alternative hypothesis is that
immunogenic switching occurs, with the
release of cytokines which act on distant
cells. There are several differences expected
between neurogenic switching and
immunogenic switching. The time required
for the onset of neurogenic switching
depends on nerve conduction velocity,
while immunogenic switching depends on
circulation time and diffusion times in tis-
sues. Neurogenic switching would directly
target a particular organ in a repetitive pat-
tern, while immunogenic switching might
have a more diffuse effect. The mechanism
bywhich the site ofinflammation is shifted
in both allergy and chemical sensitivity can
be determined experimentally, both in con-
trolled challenges in human subjects and
experimental models. Such a program
could further our understanding of these
conditions while leading to improvements
in diagnosis and treatment.
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